Pierrel SpA
MIL:PRL
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Pierrel SpA
PP&E Net
Pierrel SpA
PP&E Net Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | PP&E Net | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
P
|
Pierrel SpA
MIL:PRL
|
PP&E Net
€37.1m
|
CAGR 3-Years
40%
|
CAGR 5-Years
30%
|
CAGR 10-Years
8%
|
|
|
Newron Pharmaceuticals SpA
SIX:NWRN
|
PP&E Net
€736k
|
CAGR 3-Years
12%
|
CAGR 5-Years
0%
|
CAGR 10-Years
N/A
|
|
|
Recordati Industria Chimica e Farmaceutica SpA
MIL:REC
|
PP&E Net
€222.3m
|
CAGR 3-Years
12%
|
CAGR 5-Years
11%
|
CAGR 10-Years
7%
|
|
Pierrel SpA
Glance View
Pierrel SpA engages in the development, manufacturing, and marketing of medical therapies for the pharmaceutical, bio-pharmaceutical, and life science industries. The company is headquartered in Capua, Caserta. The company went IPO on 2006-05-23. The firm specializes in the pharmaceutical research, development and the manufacture of medicines. The company operates through three segments. The Contract Manufacturing segment covers research and development of various types of drugs, such as Tube vials, bottles, ampoules, drops, sprays, tablets and gels. The company manufactures the drugs in the production facility in Capua, which consists of warehouses, chemical and microbiological laboratories, offices and utilities buildings. The Pharma segment is active in the development, registration and licensing of new drugs and medical devices. The Tech-driven Contract Research & Development Organization segment provides research of existing drugs for the treatment of rare diseases, among others.
See Also
What is Pierrel SpA's PP&E Net?
PP&E Net
37.1m
EUR
Based on the financial report for Jun 30, 2023, Pierrel SpA's PP&E Net amounts to 37.1m EUR.
What is Pierrel SpA's PP&E Net growth rate?
PP&E Net CAGR 10Y
8%
Over the last year, the PP&E Net growth was 30%. The average annual PP&E Net growth rates for Pierrel SpA have been 40% over the past three years , 30% over the past five years , and 8% over the past ten years .
